GLP-1 Research | Incretin Pathway Guide
GLP-1 Pathway Research Guide — Receptor Pharmacology & Agonist Classes
A comprehensive research guide to GLP-1 (glucagon-like peptide-1) receptor pharmacology, the incretin pathway, and the progression from single to dual to triple receptor agonist research compounds. Includes semaglutide, tirzepatide, retatrutide, and cagrilintide pathway comparison.
GLP-1: The Foundational Incretin Pathway
Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid incretin hormone secreted by intestinal L-cells in response to nutrient intake. It activates the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed on pancreatic beta cells, alpha cells, gastric tissue, and throughout the central nervous system. GLP-1 signaling integrates metabolic homeostasis across multiple organ systems and has become one of the most researched receptor pathways in contemporary metabolic pharmacology.
GLP-1 Receptor Signaling Mechanisms
Pancreatic Effects
At the pancreatic beta cell, GLP-1R activation couples to Gαs and stimulates adenylate cyclase, increasing intracellular cAMP. This activates PKA and Epac2, which potentiate glucose-stimulated insulin secretion in a glucose-dependent manner (the “incretin effect”). At alpha cells, GLP-1R activation suppresses inappropriate glucagon secretion. This dual effect — insulin up, glucagon down — makes GLP-1R agonism mechanistically distinct from simple insulin secretagogues.
CNS and Satiety Effects
GLP-1 receptors are expressed in the hypothalamic arcuate nucleus, brainstem, and on vagal afferent neurons. Activation produces potent satiety signaling that reduces food intake and slows gastric emptying. This central mechanism is a primary contributor to the weight management effects observed in GLP-1R agonist research and is being studied for appetite regulation, reward pathway modulation, and addictive behavior circuits.
Cardiovascular Effects
GLP-1R is expressed on cardiomyocytes and endothelial cells. Research suggests GLP-1R activation has cardioprotective effects including improved endothelial function and anti-inflammatory pathway modulation.
GLP-1 Research Peptide Classes
| Generation | Receptors | Compound | Research Use |
|---|---|---|---|
| 1st — Single agonist | GLP-1R | Semaglutide | Pure GLP-1R pharmacology baseline |
| 2nd — Dual agonist | GLP-1R + GIPR | Tirzepatide | GIP receptor contribution studies |
| 3rd — Triple agonist | GLP-1R + GIPR + GCGR | Retatrutide | Full incretin + glucagon co-activation |
| Amylin combination | GLP-1R + AMY1-3 | Sema + Cagrilintide | GLP-1 + amylin dual pathway research |
Key GLP-1 Research Peptides
Related Research Pages
- GLP-1 Receptor Mechanism — In-depth receptor pharmacology
- Single vs Dual Agonist Peptides
- Triple Agonist Peptide Guide
- Retatrutide vs Tirzepatide
- Metabolic Peptide Comparison Hub
Research Use Only: All compounds referenced on this page are strictly for laboratory and in vitro research purposes only. Not intended for human use, veterinary use, or diagnostic/treatment purposes. OligoPoly Labs sells research-grade peptides exclusively to qualified researchers.